Open40.020 | Close39.950 |
Vol / Avg.732.927K / 901.497K | Mkt Cap5.277B |
Day Range39.470 - 41.064 | 52 Wk Range29.850 - 59.390 |
Halozyme Therapeutics Stock (NASDAQ: HALO) stock price, news, charts, stock research, profile.
Open40.020 | Close39.950 |
Vol / Avg.732.927K / 901.497K | Mkt Cap5.277B |
Day Range39.470 - 41.064 | 52 Wk Range29.850 - 59.390 |
Q4 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.730 | 0.750 | 0.0200 | ||||
REV | 222.630M | 216.033M | -6.597M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-10-20 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 50.00 |
2023-10-19 | HC Wainwright & Co. | Mitchell Kapoor | Maintains | BuyBuy | Raises | 60.00 | 61.00 |
2023-10-09 | HC Wainwright & Co. | Mitchell Kapoor | Reiterates | BuyBuy | Maintains | - | 60.00 |
2023-09-08 | HC Wainwright & Co. | Mitchell Kapoor | Reiterates | BuyBuy | Maintains | - | 60.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
HALO | Halozyme Therapeutics | -0.5% | 5.3B |
IMVT | Immunovant | -2.68% | 5.7B |
RARE | Ultragenyx Pharmaceutical | -2.32% | 3.3B |
MLTX | MoonLake | 2.39% | 3.4B |
KRTX | Karuna Therapeutics | -0.37% | 7.8B |
You can purchase shares of Halozyme Therapeutics (NASDAQ: HALO) through any online brokerage.
Other companies in Halozyme Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Ultragenyx Pharmaceutical (NASDAQ:RARE), MoonLake (NASDAQ:MLTX), Karuna Therapeutics (NASDAQ:KRTX) and Ionis Pharmaceuticals (NASDAQ:IONS).
The latest price target for Halozyme Therapeutics (NASDAQ: HALO) was reported by Benchmark on Friday, October 20, 2023. The analyst firm set a price target for 50.00 expecting HALO to rise to within 12 months (a possible 25.16% upside). 21 analyst firms have reported ratings in the last year.
The stock price for Halozyme Therapeutics (NASDAQ: HALO) is $39.95 last updated December 8, 2023 at 9:20 PM UTC.
There is no dividend information for Halozyme Therapeutics.
Halozyme Therapeutics’s Q4 earnings are confirmed for Tuesday, February 20, 2024.
There is no upcoming split for Halozyme Therapeutics.
Halozyme Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.